Australia shaken by complementary medicines recall

The TGA first became aware of Pan Pharmaceuticals after reports of adverse reactions to its anti-travel sickness product, Travacalm, in January. Faulty batches of the product were responsible for 19 people being admitted to hospital and 68 people having serious adverse reactions. The TGA subsequentl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2003-05, Vol.361 (9370), p.1710-1710
Hauptverfasser: Loff, Bebe, McKelvie, Helen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The TGA first became aware of Pan Pharmaceuticals after reports of adverse reactions to its anti-travel sickness product, Travacalm, in January. Faulty batches of the product were responsible for 19 people being admitted to hospital and 68 people having serious adverse reactions. The TGA subsequently found that some batches of the tablets contained up to seven times the amount of the active ingredient-hyoscine hydrobromide.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(03)13384-3